<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221815</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE</org_study_id>
    <nct_id>NCT04221815</nct_id>
  </id_info>
  <brief_title>IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>IMPact on Revascularization Outcomes of intraVascular Ultrasound Guided Treatment of Complex Lesions and Economic Impact (IMPROVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been&#xD;
      shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI.&#xD;
      This is accomplished by improving the angiographic result with lesion and vessel assessment&#xD;
      to guide stent selection and implantation and intravascular imaging following stent&#xD;
      implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive&#xD;
      literature supporting the use of IVUS in PCI, utilization remains low in the United States.&#xD;
      An increasing number of high-risk or complex lesions are being treated with PCI and we&#xD;
      hypothesize that the impact of IVUS in these complex lesions will be of increased importance&#xD;
      in reducing clinical adverse events while remaining cost effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-blind clinical investigation randomizing subjects to&#xD;
      IVUS-guided coronary stent implantation vs. angiography-guided coronary stent implantation in&#xD;
      a 1:1 ratio.&#xD;
&#xD;
      The clinical investigation will be conducted at approximately 120 centers in the US, Canada,&#xD;
      and Europe. Approximately 2,500-3,100 randomized subjects and up to 3 roll-in subjects per&#xD;
      site will be enrolled in this study. Subjects participating in this clinical investigation&#xD;
      will be followed for 2 years. The expected duration of enrollment is approximately 2.5 years.&#xD;
      The total duration of the clinical investigation is expected to be approximately 4.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IVUS core lab measures final PCI Minimum Stent Area</measure>
    <time_frame>Intra-procedural</time_frame>
    <description>The imaging primary endpoint is the final post-PCI minimum stent area (MSA) assessed by IVUS in each randomized arm, measured at an independent IVUS core laboratory blinded to treatment assignment. The MSA is an appropriate co-primary imaging endpoint as it is the most consistent and strongest parameter to predict clinical outcomes.11-14 In the present study, after 2,000 subjects are enrolled with the procedure completed, the primary endpoint of MSA will be tested to compare the IVUS-guided and angiography-guided arms. If significantly larger MSA in the IVUS-guided arm is demonstrated, the trial will continue enrolling subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF) outcomes at 12 months defined as the composite of cardiac death, target vessel related-myocardial infarction (MI), and ischemia-driven target vessel revascularization.</measure>
    <time_frame>12 months</time_frame>
    <description>The clinical primary endpoint is target vessel failure (TVF) outcomes at 12 months defined as the composite of cardiac death, target vessel related- myocardial infarction (MI), and target vessel revascularization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3100</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>IVUS guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiographic-guided PCI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eagle Eye Platinum digital IVUS catheter with optional SyncVision</intervention_name>
    <description>IVUS catheter</description>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx Drug Eluting Stent</intervention_name>
    <description>Stent</description>
    <arm_group_label>Angiographic-guided PCI</arm_group_label>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years at screening&#xD;
&#xD;
          -  PCI with stent implantation involving a high risk or complex lesion defined as&#xD;
             involving at least one of the following characteristics:&#xD;
&#xD;
          -  Chronic total occlusion&#xD;
&#xD;
          -  In-stent restenosis&#xD;
&#xD;
          -  Severe coronary artery calcification&#xD;
&#xD;
          -  Long lesion (≥ 28 mm in length)&#xD;
&#xD;
          -  Bifurcation lesion (Any Medina class that involves main branch disease with a side&#xD;
             branch ≥2.0 mm)&#xD;
&#xD;
          -  Stable angina, unstable angina, or non-ST Elevation myocardial infarction (NSTEMI),&#xD;
             undergoing PCI of a single or multivessel coronary artery stenosis&#xD;
&#xD;
          -  PCI performed with either angiography alone, or IVUS guidance used&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute ST elevation myocardial infarction (STEMI), or cardiogenic shock&#xD;
&#xD;
          -  Use of fibrinolytic therapy within 24 hours of PCI&#xD;
&#xD;
          -  Planned revascularization as a staged procedure&#xD;
&#xD;
          -  Stent thrombosis&#xD;
&#xD;
          -  Use of optical coherence tomography (OCT) during the index procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Megan Rowland, MPH</last_name>
    <phone>2028772959</phone>
    <email>megan.e.rowland@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Rowland, MPH</last_name>
      <email>megan.e.rowland@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Itsik Ben-Dor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manatee Memorial Hospital</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Mathews, MD</last_name>
      <email>sjaymathewsmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Santosh Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa Cardiovascular/St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saihari Sadanandan, MD</last_name>
      <email>saihari.sadanandan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Saihari Sadanandan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wissam A Jaber, MD</last_name>
      <email>wissam.jaber@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Wissam A Jaber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Issam Moussa, MD</last_name>
      <email>moussa.issam@carle.com</email>
    </contact>
    <investigator>
      <last_name>Issam Moussa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MercyOne Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdi Ghali, MD</last_name>
      <email>mghali@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Magdi Ghali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - South Shore University Hospital</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Gruberg, MD</last_name>
      <email>lgruberg@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Gruberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Gruberg, MD</last_name>
      <email>lgruberg@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Gruberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Lennox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Gruberg, MD</last_name>
      <email>lgruberg@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Gruberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailendra Singh, MD</last_name>
      <email>shailendra.singh@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Shailendra Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gajjar, MD</last_name>
      <email>mark.gajjar@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Mark Gajjar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Regional Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suraj Rasania, MD</last_name>
      <email>srasania@sarh.org</email>
    </contact>
    <investigator>
      <last_name>Suraj Rasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

